These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9725547)

  • 1. Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers.
    Mazzu A; Lettieri J; Kaiser L; Mullican W; Heller AH
    J Clin Pharmacol; 1998 Aug; 38(8):715-9. PubMed ID: 9725547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.
    Weber P; Lettieri JT; Kaiser L; Mazzu AL
    Clin Ther; 1999 Sep; 21(9):1563-75. PubMed ID: 10509851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults.
    Isaacsohn J; Zinny M; Mazzu A; Lettieri J; Heller AH
    Eur J Clin Pharmacol; 2001 Mar; 56(12):897-903. PubMed ID: 11317478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults.
    Mazzu AL; Lettieri JT; Kelly E; Vargas R; Marbury T; Liu MC; Sundaresan P
    Eur J Clin Pharmacol; 2000 Apr; 56(1):69-74. PubMed ID: 10853881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
    Mück W; Ochmann K; Rohde G; Unger S; Kuhlmann J
    Eur J Clin Pharmacol; 1998 Feb; 53(6):469-73. PubMed ID: 9551706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of itraconazole on cerivastatin pharmacokinetics.
    Kantola T; Kivistö KT; Neuvonen PJ
    Eur J Clin Pharmacol; 1999 Jan; 54(11):851-5. PubMed ID: 10027660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
    Plosker GL; Dunn CI; Figgitt DP
    Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
    Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
    Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
    Stein E; Isaacsohn J; Stoltz R; Mazzu A; Liu MC; Lane C; Heller AH
    Am J Cardiol; 1999 May; 83(10):1433-6. PubMed ID: 10335757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
    Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.
    Mück W; Park S; Jäger W; Voith B; Wandel E; Galle PR; Schwarting A
    Int J Clin Pharmacol Ther; 2001 May; 39(5):192-8. PubMed ID: 11380064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
    Mück W; Ochmann K; Mazzu A; Lettieri J
    J Int Med Res; 1999; 27(3):107-14. PubMed ID: 10505300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemfibrozil greatly increases plasma concentrations of cerivastatin.
    Backman JT; Kyrklund C; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2002 Dec; 72(6):685-91. PubMed ID: 12496749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients.
    Renders L; Haas CS; Liebelt J; Oberbarnscheidt M; Schöcklmann HO; Kunzendorf U
    Br J Clin Pharmacol; 2003 Aug; 56(2):214-9. PubMed ID: 12895195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening.
    Mück W; Frey R; Unger S; Voith B
    Int J Clin Pharmacol Ther; 2000 Jun; 38(6):298-303. PubMed ID: 10890578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
    Stein EA
    Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety.
    Stein E
    Atherosclerosis; 1998 Sep; 139 Suppl 1():S15-22. PubMed ID: 9811154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of cerivastatin.
    Mück W
    Clin Pharmacokinet; 2000 Aug; 39(2):99-116. PubMed ID: 10976657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.
    Mück W; Ritter W; Dietrich H; Frey R; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of drug-drug interaction between cerivastatin and nifedipine.
    Sachse R; Brendel E; Mück W; Rohde G; Ochmann K; Horstmann R; Kuhlmann J
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):409-13. PubMed ID: 9726692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.